Home > Research > Publications & Outputs > Cohort profile

Links

Text available via DOI:

View graph of relations

Cohort profile: HAART observational medical evaluation and research (HOMER) cohort

Research output: Contribution to journalJournal articlepeer-review

Published
  • S. Patterson
  • A. Cescon
  • H. Samji
  • Z. Cui
  • B. Yip
  • K.J. Lepik
  • D. Moore
  • V.D. Lima
  • B. Nosyk
  • P. Richard Harrigan
  • J.S.G. Montaner
  • K. Shannon
  • E. Wood
  • R.S. Hogg
Close
<mark>Journal publication date</mark>28/02/2015
<mark>Journal</mark>International Journal of Epidemiology
Issue number1
Volume44
Number of pages10
Pages (from-to)58-67
Publication StatusPublished
Early online date17/03/14
<mark>Original language</mark>English

Abstract

Since 1986, antiretroviral therapy (ART) has been available free of charge to individuals living with HIV in British Columbia (BC), Canada, through the BC Centre of Excellence in HIV/AIDS (BC-CfE) Drug Treatment Program (DTP). The Highly Active Antiretroviral Therapy (HAART) Observational Medical Evaluation and Research (HOMER) cohort was established in 1996 to maintain a prospective record of clinical measurements and medication profiles of a subset of DTP participants initiating HAART in BC. This unique cohort provides a comprehensive data source to investigate mortality, prognostic factors and treatment response among people living with HIV in BC from the inception of HAART. Currently over 5000 individuals are enrolled in the HOMER cohort. Data captured include socio-demographic characteristics (e.g. sex, age, ethnicity, health authority), clinical variables (e.g. CD4 cell count, plasma HIV viral load, AIDS-defining illness, hepatitis C co-infection, mortality) and treatment variables (e.g. HAART regimens, date of treatment initiation, treatment interruptions, adherence data, resistance testing). Research findings from the HOMER cohort have featured in numerous high-impact peer-reviewed journals. The HOMER cohort collaborates with other HIV cohorts on both national and international scales to answer complex HIV-specific research questions, and welcomes input from external investigators regarding potential research proposals or future collaborations. For further information please contact the principal investigator, Dr Robert Hogg (robert_hogg@sfu.ca).